Advertisements

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.095 0.00 (0.00%) Volume: 0 9:30 AM EST Mar 4, 2015
Today 5d 1m 3m 1y more
Last Price
0.095
Change $
Change %
Tick
  
Bid
0.075
Bid Size
1,000
Ask
0.095
Ask Size
19,000
Open
N/A
High
N/A
Low
N/A
Prev Close
0.095
Last Trade
03/04/15
Volume
0
52 Wk Hi
0.24
52 Wk Low
0.02
Market Cap
8.88m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
93,469,236
EPS (TTM)
-0.07
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Tue, Feb 10, 2015
12:41 PM IIROC Trade Resumption - PVO - Canada Newswire
12:28 PM Pivotal announces the issuance of two patents both related to the combination of VASCAZEN\u00AE with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors - Canada Newswire
12:28 PM Pivotal announces the issuance of two patents both related to the combination of VASCAZEN\u00AE with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors - PR Newswire
12:24 PM IIROC Trading Halt - PVO - Canada Newswire
Tue, Jan 27, 2015
1:23 PM Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100 - Canada Newswire
1:23 PM Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100 - PR Newswire
Thu, Jan 22, 2015
3:38 PM Pivotal Therapeutics: Year in Review and CEO Update - Canada Newswire
3:38 PM Pivotal Therapeutics: Year in Review and CEO Update - PR Newswire
Mon, Jan 05, 2015
5:10 PM Pivotal Therapeutics announces payment of interest on outstanding convertible notes - Canada Newswire
5:10 PM Pivotal Therapeutics announces payment of interest on outstanding convertible notes - PR Newswire
Wed, Dec 17, 2014
7:32 AM VASCAZEN\u00AE POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA - PR Newswire
7:30 AM VASCAZEN\u00AE POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA - PR Newswire
7:30 AM VASCAZEN\u00AE POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA - Canada Newswire
Fri, Nov 28, 2014
5:22 PM Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results - Canada Newswire
5:22 PM Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results - PR Newswire
Fri, Nov 14, 2014
3:15 PM Pivotal Therapeutics Announces Senior Management Change - Canada Newswire
3:15 PM Pivotal Therapeutics Announces Senior Management Change - PR Newswire
Wed, Oct 08, 2014
3:00 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - Canada Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.